Image source: Getty Images.Shares of Geron Corporation (NASDAQ: GERN), a clinical-stage small-cap biotech focused on the development of treatments for cancer, plunged 18% in October based on data from S&P Global Market Intelligence. The reason for the drop can likely be traced to the impatience of investors.In September, Geron and licensing partner Johnson & Johnson (NYSE: JNJ) (via its subsidiary Janssen Pharmaceuticals) provided updates on two critical studies involving Geron's lead drug, imetelstat.Continue reading